Abstract
Objectives
To determine the effect of implementing a 2015 policy for the screening, prevention, and management of metabolic bone disease for very low birth weight (VLBW) infants in two Level IV NICUs.
Study design
Retrospective cohort study of VLBW infants in the 2 years prior to (2013–2014) and after (2016–2017) policy implementation.
Results
We identified 316 VLBW infants in 2013–2014 and 292 in 2016–2017 who met study criteria. After policy implementation, vitamin D supplementation began earlier (20.1 ± 15.5 days vs 30.2 ± 20.1 days, p < 0.0005), the percentage of infants with alkaline phosphatase obtained increased (89.7% vs 76.3%, p < 0.0005), while the percentage of infants with alkaline phosphatase >800 IU/L (11.7 vs 4.5%, p = 0.0001) and phosphorous <4 mg/dL (14.2% vs 7.9%, p = 0.014) fell significantly.
Conclusions
After policy implementation, vitamin D supplementation began significantly earlier and the rate of detecting abnormal biochemical markers of metabolic bone disease decreased significantly.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rustico SE, Calabria AC, Garber SJ. Metabolic bone disease of prematurity. J Clin Transl Endocrinol. 2014;1:85–91.
Backström MC, Kuusela AL, Mäki R. Metabolic bone disease of prematurity. Ann Med 1996;28:275–82.
Takada M, Shimada M, Hosono S, Tauchi M, Minato M, Takahashi S, et al. Trace elements and mineral requirements for very low birth weight infants in rickets of prematurity. Early Hum Dev. 1992;29:333–8.
Harrison CM, Johnson K, McKechnie E. Osteopenia of prematurity: a national survey and review of practice. Acta Paediatr. 2008;97:407–13.
Mitchell SM, Rogers SP, Hicks PD, Hawthorne KM, Parker BR, Abrams SA. High frequencies of elevated alkaline phosphatase activity and rickets exist in extremely low birth weight infants despite current nutritional support. BMC Pediatr. 2009;9:47.
Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. Pediatrics. 2013;131:e1676–83.
Kelly A, Kovatch KJ, Garber SJ. Metabolic bone disease screening practices among U.S. neonatologists. Clin Pediatr (Philos). 2014;53:1077–83.
Chinoy A, Mughal MZ, Padidela R. Metabolic bone disease of prematurity: causes, recognition, prevention, treatment, and long-term consequences. Arch Dis Child Fetal Neonatal Ed. 2019;104:F560–6.
Rayannavar A, Calabria AC. Screening for metabolic bone disease of prematurity. Semin Fetal Neonatal Med. 2020;25:101086.
Hung YL, Chen PC, Jeng SF, Hsieh CJ, Peng SS, Yen RF, et al. Serial measurements of serum alkaline phosphatasefor early prediction of osteopaenia in preterm infants. J Paediatr Child Health. 2011;47:134–9.
Abdallah EA, Said RN, Mosallam DS, Moawad EM, Kamal NM, Fathallah MG. Serial serum alkaline phosphatase as an early biomarker for osteopenia of prematurity. Medicine (Baltimore). 2016;95:e4837.
Backstrom MC, Kouri T, Kuusela AL, Sievänen H, Koivisto AM, Ikonen RS, et al. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. Acta Paediatr. 2000;89:867–73.
Lee J, Park HK, Kim JH, Choi YY, Lee HJ. Bone mineral density according to dual energy X-ray absorptiometry is associated with serial serum alkaline phosphatase level in extremely low birth weight infants at discharge. Pediatr Neonatol. 2017;58:251–7.
Moreira A, Swischuk L, Malloy M, Mudd D, Blanco C, Geary C. Parathyroid hormone as a marker for metabolic bone disease of prematurity. J Perinatol. 2014;34:787–91.
Acknowledgements
We thank Dr. Reese Clark, Dr. Veeral Tolia, and Dr. Blanca Molina for their critical review of this manuscript. We thank our quality improvement team for support of this protocol after initiation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors have indicated that they have no potential conflict of interest to disclose. The views expressed in this publication represent those of the authors and do not necessarily represent the official views of HCA or any of its affiliated entities.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Sabroske, E.M., Payne, D.H., Stine, C.N. et al. Effect on metabolic bone disease markers in the neonatal intensive care unit with implementation of a practice guideline. J Perinatol 40, 1267–1272 (2020). https://doi.org/10.1038/s41372-020-0693-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-020-0693-2